FEZF1 and adenocarcinoma: FENDRR hypermethylation was more frequent in adenocarcinomas (56.9%) than in squamous cell carcinomas (21.6%, p = 5.5 × 10–5) while an opposite borderline trend was found for FEZF1-AS1 (37.3% vs 55.3%, p = 0.05, Table 2).